ArticleEJNMMI physics2022
Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [
Article in EJNMMI physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 13 citations in OpenAlex.
- Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [European journal of nuclear medicine and molecular imaging · 2026Trial
- Safety and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Trial
- [JMIR research protocols · 2026Article
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Effect of previousAnnals of nuclear medicine · 2026Article
- Expanding the therapeutic horizon ofNagoya journal of medical science · 2025Review
- CanJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- From Seeing to Healing: The Clinical Potential of Radiotracers in Pediatric Neuro-Oncology.Cancers · 2025Review
- Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Role ofFrontiers in medicine · 2025Article
- Prediction of [EJNMMI physics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeRecent reports personalizing the administered activity (AA) of each cycle of peptide receptor radionuclide therapy based on the predicted absorbed dose (AD) to the kidneys (dose-limiting organ) have been promising. Assuming identical renal pharmacokinetics for each cycle is pragmatic, however it may lead to over- or under-estimation of the optimal AA. Here, we investigate the influence that earlier cycles of [
methodsA simulation study, based on dosimetry data from six children with NBL who received four-cycles of [
resultsThe median tumour AD per cycle was found to decrease from 15.6 Gy (range 8.12-26.4) in cycle 1 to 11.4 Gy (range 9.67-28.8), 11.3 Gy (range 2.73-32.9) and 4.3 Gy (range 0.72-20.1) in cycles 2, 3 and 4, respectively. By the fourth cycle, the median of the ratios of the delivered AD (AD
conclusionThis study demonstrates variability in Gy/GBq and tumour AD per cycle in children receiving four administrations of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.